NCT02411448 2026-01-16
RELAY
Eli Lilly and Company
Phase 3 Active not recruiting
Clinical Trials
17 trialsNCT03694002 2025-10-30
Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
SWOG Cancer Research Network
Phase 2 Completed
NCT04120454 2025-07-11
Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT04394624 2025-06-06
CARMEN-LC04
Sanofi
Phase 2 Terminated
NCT03971474 2024-09-03
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
SWOG Cancer Research Network
Phase 2 Completed
NCT02443324 2024-07-31
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03689855 2024-07-30
RamAtezo-1
Washington University School of Medicine
Phase 2 Completed
NCT03502746 2024-05-14
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02789345 2024-02-05
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03904108 2022-05-26
Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy
Stony Brook University
Phase 2 Terminated
NCT02082210 2020-12-19
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT02730247 2020-11-19
Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
University of Pittsburgh
Phase 2 Completed
NCT02079636 2020-09-11
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 1 Completed
NCT01703091 2019-09-30
A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01168973 2019-09-25
A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy
Eli Lilly and Company
Phase 3 Completed
NCT01160744 2019-09-13
A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 2 Completed
NCT00735696 2014-12-29
A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed